Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer

Репотрецтиниб при немелкоклеточном раке легкого с ROS1-реаранжировкой
Rafał Dziadziuszko, Enriqueta Felip, Shun Lü, Byoung Chul Cho, Misako Nagasaka, Nong Yang, D. Ross Camidge, Benjamin Solomon, Ki Hyeong Lee, Alexander Edward Dela Cruz Drilon, Matthew Krebs, Jessica J. Lin, Vamsidhar Velcheti, Sanjay Popat, Minal Mehta, Jürgen Wolf, Muhammad Shaalan Beg, Yong Yuan, Kōichi Goto, Christoph Springfeld, Denis Moro‐Sibilot, Benjamin Besse, Sang‐We Kim, Christophe Dooms, Parneet Kaur Cheema, Steven Kao, Adrianus Johannes De Langen, Wenxiu Yao, Xiufeng Hu, Shanna Stopatschinskaja, Denise Trone, Armin Graber, Gregory E. Sims
2024-01-10

G2032R mutationPhase 2 TRIDENT-1 trial (NCT03093116)ROS1 fusion–positive non–small-cell lung cancerRepotrectinibTreatment-related adverse events (dizziness, dysgeusia, paresthesia)
The early-generation ROS1 tyrosine kinase inhibitors (TKIs) that are approved for the treatment of ROS1 fusion–positive non–small-cell lung cancer (NSCLC) have antitumor activity, but resistance develops in tumors, and intracranial activity is suboptimal. Repotrectinib is a next-generation ROS1 TKI with preclinical activity against ROS1 fusion–positive cancers, including those with resistance mutations such as ROS1 G2032R. Download a PDF of the Research Summary. In this registrational phase 1–2 trial, we assessed the efficacy and safety of repotrectinib in patients with advanced solid tumors, including ROS1 fusion–positive NSCLC. The primary efficacy end point in the phase 2 trial was confirmed objective response; efficacy analyses included patients from phase 1 and phase 2. Duration of response, progression-free survival, and safety were secondary end points in phase 2. On the basis of results from the phase 1 trial, the recommended phase 2 dose of repotrectinib was 160 mg daily for 14 days, followed by 160 mg twice daily. Response occurred in 56 of the 71 patients (79%; 95% confidence interval [CI], 68 to 88) with ROS1 fusion–positive NSCLC who had not previously received a ROS1 TKI; the median duration of response was 34.1 months (95% CI, 25.6 to could not be estimated), and median progression-free survival was 35.7 months (95% CI, 27.4 to could not be estimated). Response occurred in 21 of the 56 patients (38%; 95% CI, 25 to 52) with ROS1 fusion–positive NSCLC who had previously received one ROS1 TKI and had never received chemotherapy; the median duration of response was 14.8 months (95% CI, 7.6 to could not be estimated), and median progression-free survival was 9.0 months (95% CI, 6.8 to 19.6). Ten of the 17 patients (59%; 95% CI, 33 to 82) with the ROS1 G2032R mutation had a response. A total of 426 patients received the phase 2 dose; the most common treatment-related adverse events were dizziness (in 58% of the patients), dysgeusia (in 50%), and paresthesia (in 30%), and 3% discontinued repotrectinib owing to treatment-related adverse events. Repotrectinib had durable clinical activity in patients with ROS1 fusion–positive NSCLC, regardless of whether they had previously received a ROS1 TKI. Adverse events were mainly of low grade and compatible with long-term administration. (Funded by Turning Point Therapeutics, a wholly owned subsidiary of Bristol Myers Squibb; TRIDENT-1 ClinicalTrials.gov number, NCT03093116.) QUICK TAKE VIDEO SUMMARYRepotrectinib in ROS1 Fusion–Positive Lung Cancer 02:17
1
Among 426 patients receiving the phase 2 dose, the most common treatment-related adverse events were dizziness (58%), dysgeusia (50%), and paresthesia (30%).
2
Efficacy analyses pooled patients from phase 1 and phase 2, with secondary end points including duration of response and progression-free survival.
3
Repotrectinib demonstrated activity in ROS1 fusion–positive NSCLC regardless of prior receipt of a ROS1 tyrosine kinase inhibitor.
4
Repotrectinib induced responses in tumors harboring the ROS1 G2032R resistance mutation.
5
Repotrectinib showed confirmed objective responses in patients with ROS1 fusion–positive non–small-cell lung cancer enrolled in the trial.
6
Treatment-related adverse events led to discontinuation of repotrectinib in 3% of patients, and most adverse events were low grade and compatible with long-term administration.

Repotrectinib treatment in ROS1 fusion–positive non–small-cell lung cancer patients

Efficacy (confirmed objective response, duration of response, progression-free survival) and safety (treatment-related adverse events, discontinuation rates) of repotrectinib in ROS1 fusion–positive NSCLC, including patients with prior ROS1 TKI exposure and G2032R mutation responses

Publication Details
Publication Date
2024-01-10
Journal
Publisher
ISSN
Cited by
239
Access Type
Author Information
Authors
Rafał Dziadziuszko
Enriqueta Felip
Shun Lü
Byoung Chul Cho
Misako Nagasaka
Nong Yang
D. Ross Camidge
Benjamin Solomon
Ki Hyeong Lee
Alexander Edward Dela Cruz Drilon
Matthew Krebs
Jessica J. Lin
Vamsidhar Velcheti
Sanjay Popat
Minal Mehta
Jürgen Wolf
Muhammad Shaalan Beg
Yong Yuan
Kōichi Goto
Christoph Springfeld
Denis Moro‐Sibilot
Benjamin Besse
Sang‐We Kim
Christophe Dooms
Parneet Kaur Cheema
Steven Kao
Adrianus Johannes De Langen
Wenxiu Yao
Xiufeng Hu
Shanna Stopatschinskaja
Denise Trone
Armin Graber
Gregory E. Sims
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%